Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral hexaminolevulinate (HAL) fluorescence imaging in colon neoplasia
2008-001711-38Phase 2Terminated
- Sponsor
- Photocure
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hexaminolevulinate in colorectal neoplasm, colon adenoma and colorectal cancer (CRC), sponsored by Photocure. Primary endpoints: True detection rate of carcinoma and adenoma lesions with HAL fluorescence colonoscopy and False detection rate of carcinoma and adenoma lesions with HAL fluorescence colonoscopy. Started Aug 2008; status: terminated.
02
Drugs
hexaminolevulinate
03
Conditions
colorectal neoplasmcolon adenomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-001711-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001711-38.